PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall survival or progression-free ...

T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...